Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg highlights recovery potential, cheap valuation at JD Sports

(Sharecast News) - Berenberg has reiterated a 'buy' recommendation for JD Sports despite an underwhelming set of interim results this week, citing the stock's low valuation and the company's potential for a recovery. First-half pre-tax profit of £351m was close to the retailer's implied guidance of £354m, representing 40% of the full-year consensus forecast, which stood at £885m prior to the results.

That has since come down to £878m - implied by the guidance range of £853m-914m - though Berenberg has trimmed its own estimate from £782m to £865m due to updated FX translation rates.

"We continue to expect lfl sales to be down by 2.5% in H2, the same rate as seen in H1, while the gross margin could continue to dip as a result of the business mix and a promotional UK online sports fashion market," the broker said.

Nevertheless, Berenberg said it remains "constructive on the company's recovery potential", with the 2026 FIFA World Cup next summer expected to bring a "halo effect" to the sportswear market. Meanwhile, the broker highlighted the company's recent work to catch up on technology and logistics infrastructure, as it ramps up its new Heerlen distribution centre in the Netherlands.

"At c7x forward P/E (January 2027E), the stock continues to look cheap, in our view, even if we await a lfl sales recovery as the likely catalyst required for a re-rating," the broker said.

Berenberg left its 155p target price for the stock unchanged, implying significant upside to Thursday afternoon's price of 89.32p (up 1.6% on the day).

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.